Bernardini Nicoletta, Dattola Annunziata, Caldarola Giacomo, Orsini Diego, Assorgi Chiara, D'Amore Alessandra, Maretti Giulia, Richetta Antonio Giovanni, Tolino Ersilia, Skroza Nevena, Potenza Concetta
Dermatology Unit "Daniele Innocenzi", ASL Latina, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Italy.
Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy.
Drugs Context. 2024 May 23;13. doi: 10.7573/dic.2024-1-4. eCollection 2024.
Psoriasis is a chronic inflammatory disease that can affect any part of the body but, when it appears in certain areas, like the face, it can have a very significant psychological impact. Biologics, in particular IL-17 and IL-23 drug inhibitors, have shown relevant clinical efficacy in the management of psoriatic lesions in difficult-to-treat areas. In post hoc analysis of phase III trials in plaque psoriasis, bimekizumab has shown safety and complete clearance of high-impact areas. However, these studies did not focus on the effect of bimekizumab on facial lesions. Therefore, this case series represents the first clinical real-life experience of rapid and successful management of facial psoriasis with bimekizumab in six patients.
银屑病是一种慢性炎症性疾病，可累及身体的任何部位，但当它出现在某些部位，如面部时，可能会产生非常重大的心理影响。生物制剂，特别是白细胞介素-17和白细胞介素-23药物抑制剂，在治疗难治性部位的银屑病皮损方面已显示出相关的临床疗效。在斑块状银屑病III期试验的事后分析中，比美吉珠单抗已显示出安全性以及对高影响区域的完全清除效果。然而，这些研究并未关注比美吉珠单抗对面部皮损的影响。因此，本病例系列代表了6例患者使用比美吉珠单抗快速且成功治疗面部银屑病的首例临床实际经验。
